DK3848369T3 - N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf - Google Patents

N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf Download PDF

Info

Publication number
DK3848369T3
DK3848369T3 DK21157420.7T DK21157420T DK3848369T3 DK 3848369 T3 DK3848369 T3 DK 3848369T3 DK 21157420 T DK21157420 T DK 21157420T DK 3848369 T3 DK3848369 T3 DK 3848369T3
Authority
DK
Denmark
Prior art keywords
methyl
aminosulfonyl
thiazol
pyridinyl
acetamide
Prior art date
Application number
DK21157420.7T
Other languages
English (en)
Inventor
Yogeshwar Bachhav
Wilfried Schwab
Alexander Birkmann
Kurt Voegtli
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57421711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3848369(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Application granted granted Critical
Publication of DK3848369T3 publication Critical patent/DK3848369T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK21157420.7T 2016-11-28 2017-11-28 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf DK3848369T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16200967 2016-11-28
EP17811883.2A EP3544976B1 (en) 2016-11-28 2017-11-28 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof

Publications (1)

Publication Number Publication Date
DK3848369T3 true DK3848369T3 (da) 2023-03-27

Family

ID=57421711

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21157420.7T DK3848369T3 (da) 2016-11-28 2017-11-28 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf
DK17811883.2T DK3544976T3 (da) 2016-11-28 2017-11-28 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17811883.2T DK3544976T3 (da) 2016-11-28 2017-11-28 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf

Country Status (21)

Country Link
US (2) US11021474B2 (da)
EP (3) EP4201934A1 (da)
JP (2) JP6978501B2 (da)
KR (2) KR102622289B1 (da)
CN (2) CN109996798B (da)
AR (1) AR110249A1 (da)
AU (3) AU2017365632B2 (da)
CA (1) CA3045059A1 (da)
CY (1) CY1124523T1 (da)
DK (2) DK3848369T3 (da)
ES (2) ES2941390T3 (da)
HR (1) HRP20210720T1 (da)
HU (1) HUE054703T2 (da)
LT (1) LT3544976T (da)
PL (1) PL3544976T3 (da)
PT (2) PT3544976T (da)
RS (1) RS61905B1 (da)
SI (2) SI3848369T1 (da)
TW (2) TWI811800B (da)
UY (1) UY37496A (da)
WO (1) WO2018096170A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
CN109996798B (zh) * 2016-11-28 2023-05-05 艾库里斯有限及两合公司 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙酰胺游离碱半水合物、其制造方法和用途
JP7316214B2 (ja) * 2016-11-28 2023-07-27 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｎ－［５－（アミノスルホニル）－４－メチル－１，３－チアゾール－２－イル］－ｎ－メチル－２－［４－（２－ピリジニル）－フェニル］－アセトアミドの遊離塩基形のマレイン酸塩、医薬製剤、製造方法およびヘルペスウイルスの処置のためのその使用
AR113344A1 (es) 2017-10-05 2020-04-22 Innovative Molecules Gmbh Enantiómeros de una serie de compuestos antivirales
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
EP3925595A1 (en) * 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
EP4096632A1 (en) * 2020-03-26 2022-12-07 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate
WO2024047507A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024047506A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496820A (en) * 1988-10-20 1996-03-05 Peraelampi; Markku Ophthalmic use of S-timolol hemihydrate
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
CN109996798B (zh) 2016-11-28 2023-05-05 艾库里斯有限及两合公司 N-[5-(氨基磺酰基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙酰胺游离碱半水合物、其制造方法和用途
JP7316214B2 (ja) * 2016-11-28 2023-07-27 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｎ－［５－（アミノスルホニル）－４－メチル－１，３－チアゾール－２－イル］－ｎ－メチル－２－［４－（２－ピリジニル）－フェニル］－アセトアミドの遊離塩基形のマレイン酸塩、医薬製剤、製造方法およびヘルペスウイルスの処置のためのその使用
EP4096632A1 (en) * 2020-03-26 2022-12-07 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate

Also Published As

Publication number Publication date
CN109996798B (zh) 2023-05-05
JP6978501B2 (ja) 2021-12-08
TWI737861B (zh) 2021-09-01
CN109996798A (zh) 2019-07-09
SI3544976T1 (sl) 2021-08-31
AU2017365632B2 (en) 2021-07-15
US20200123145A1 (en) 2020-04-23
KR20190085115A (ko) 2019-07-17
TW201825483A (zh) 2018-07-16
SI3848369T1 (sl) 2023-07-31
EP3848369A1 (en) 2021-07-14
US20210269429A1 (en) 2021-09-02
EP4201934A1 (en) 2023-06-28
RS61905B1 (sr) 2021-06-30
JP2022024043A (ja) 2022-02-08
AR110249A1 (es) 2019-03-13
TWI811800B (zh) 2023-08-11
CN116804007A (zh) 2023-09-26
HUE054703T2 (hu) 2021-09-28
CY1124523T1 (el) 2022-07-22
PL3544976T3 (pl) 2021-11-02
AU2021221901A1 (en) 2021-09-23
TW202207924A (zh) 2022-03-01
KR102536156B1 (ko) 2023-05-25
ES2941390T3 (es) 2023-05-22
KR20230075524A (ko) 2023-05-31
CA3045059A1 (en) 2018-05-31
ES2870614T3 (es) 2021-10-27
EP3544976A1 (en) 2019-10-02
EP3544976B1 (en) 2021-02-17
LT3544976T (lt) 2021-08-10
KR102622289B1 (ko) 2024-01-05
WO2018096170A9 (en) 2019-12-19
JP7289891B2 (ja) 2023-06-12
JP2020509991A (ja) 2020-04-02
DK3544976T3 (da) 2021-05-10
AU2017365632A1 (en) 2019-06-13
AU2021221901B2 (en) 2022-08-11
PT3848369T (pt) 2023-04-10
UY37496A (es) 2018-06-29
HRP20210720T1 (hr) 2021-09-03
US11021474B2 (en) 2021-06-01
PT3544976T (pt) 2021-05-18
WO2018096170A1 (en) 2018-05-31
AU2022263540A1 (en) 2022-12-08
EP3848369B1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
DK3848369T3 (da) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamid-fri base hæmihydrat, fremgangsmåder til fremstilling og anvendelser deraf
NO2022023I1 (no) Ponesimod (IUPAC name: (R)-5-[3-chloro-4-(2,3-dih ydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolylthiazolidin-4-one) and harmaceutically acceptable salts thereof
DK3535298T3 (da) Antistoffer til pd-1 og brug deraf
DK3978580T3 (da) Stabiliserede fluorolefinsammensætninger og fremgangsmåde til fremstilling, oplagring og anvendelse deraf
DK3319434T3 (da) Herbicidsammensætning, der omfatter cinmethylin og pethoxamid
DK3385262T3 (da) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
DK2602258T3 (da) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid-mesylat-monohydrat
DK3486242T3 (da) Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf
PT3544977T (pt) Um sal maleato da base livre de n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulações farmacêuticas, métodos de produção e suas utilizações para o tratamento de vírus herpes
DK3255046T3 (da) Hydroxyethylsulfonat af cyclin-afhængig proteinkinasehæmmer, krystallinsk form deraf og fremgangsmåde til fremstilling deraf
DK3515910T3 (da) 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma
DK3120710T3 (da) Fremgangsmåde til at fremstille ostechips og hævede ostechips
DK3256479T3 (da) 4-substituerede benzoxaborolforbindelser og anvendelser deraf
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
SI3559010T1 (sl) Postopek za pripravo 5-((4-(2-(5-(1-hidroksietil)-2-piridinil)etoksi) fenil)metil)-2,4-tiazolidindiona in soli le-tega
IL272992A (en) Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
ZA202000224B (en) 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof
DK3250188T3 (da) Farmaceutisk sammensætning, der omfatter aprepitant, og fremgangsmåde til fremstilling deraf
SI3292133T1 (sl) Postopek priprave 2-(4-(2-(((2-(4-klorofenil)-1,3-tiazol-4-il)metil)sulfanil)-3,5-dician- 6-(pirolidin-1-il)piridin-4-il)fenoksi)etil-L-alanil-L-alaninat hidroklorida
IL265893A (en) Crystal forms of 4-(2-((r1(2r,-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-n-methylpicolinamide
DK3331505T3 (da) Farmaceutisk sammensætning, som omfatter et atypisk antipsykotisk middel og en fremgangsmåde til fremstilling deraf
PT2602258E (pt) Monohidrato de mesilato de n-[5-aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida
TH1601002607A (th) สารประกอบพิริดิลซึ่งถูกแทนที่ด้วยแอลคิล-แอมีดที่ใช้ประโยชน์เป็นสารควบคุม การตอบสนองของ IL-12, IL-23 และ/หรือ IFNalpha